Cystoscopy Cystoscopy and Stent Removal Cystoscopy and Biopsy PATIENT INSTRUCTIONS and CONSENT FORM.
The ROS1 Cancer Model Project: a unique patient-driven ... · implants tumor into mouse* Remote...
1
METHODS The ROS1 Cancer Model Project is part of the Global ROS1 Initiative, a powerful partnership between patients & caregivers, advocacy organizations, researchers and industry that, when combined with social media outreach, has increased the available oncogene-driven patient data, specimens, and cancer models for rare, geographically-distributed pan-cancer patient populations. Current efforts are focused on growing the number of models available and disseminating them for research. CONCLUSIONS The ROS1 Cancer Model Project: a unique patient-driven partnership to accelerate research Amy C. Moore 1 , Lisa Goldman 2 , Tori Tomalia 2 , Robert C. Doebele 3 , Christine M. Lovly 4 , Rachel Chiaverelli 5 , Tony Addario 6 , Alicia Sable-Hunt 6 , Bonne J. Addario 1 , Janet Freeman-Daily 2 1 GO 2 Foundation for Lung Cancer, San Carlos, CA, 2 The ROS1ders Inc., Mountain View, CA, 3 University of Colorado Denver, Aurora, CO, 4 Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, 5 Champions Oncology Inc., Hackensack, NJ, 6 Addario Lung Cancer Medical Institute, San Carlos, CA • >500 English-speaking ROS1+ patients & caregivers • 6 continents • 28 countries • 8 ROS1+ cancer types Co-Creation of Preclinical Cancer Models Dissemination of Annotated ROS1+ Models Collect Patient Medical Records & Specimens Model Creation, Analysis, Data Interpretation Other Tumors Can Harbor ROS1+ • angiosarcoma • breast cancer • cervical cancer • cholangiocarcinoma • colon cancer • epithelioid hemangioendothelioma • gastric cancer • glioblastoma • inflammatory myofibroblastic tumor • liver cancer • melanoma • ovarian cancer • pancreatic cancer • Rare (only 3% of NSCLC and other cancers) • Few cancer clinics or doctors are familiar with ROS1 cancer or encounter ROS1+ patients • NSCLC patients are not always tested for ROS1 (even though ROS1+ NSCLC has two FDA- approved drugs), and other cancers are almost never tested for ROS1 • ROS1 can fuse with 20+ genes, but had only 1 PDX model & a few cell lines in 01/2017 Pan-Cancer Challenges of ROS1 Rearrangements To date we have created 8 new cell lines (which doubled the available ROS1 cell lines) and initiated 5 PDX mouse models. Three cell lines have been genomically characterized (two ROS1-CD74, one ROS1-TPM3). The cell lines have been shared with five other institutions researching ROS1 cancers: UCSF, Huntsman Cancer Institute, NIH, Moffitt Cancer Center, and Ignyta (now Roche). The cells lines have been used in three published ROS1 journal articles, among them an analysis of ROS1 resistance mechanisms to targeted therapies (left). PRELIMINARY RESULTS Thanks to all ROS1 clinicians, researchers, patients, caregivers, supporters, and partners who make the ROS1 Cancer Model Project possible. Jeff Wynne collected data for the ROS1der demographics. Funding and in-kind support for the Global ROS1 Initiative is provided by individual ROS1ders, Addario Lung Cancer Medical Institute, GO 2 Foundation for Lung Cancer, Champions Oncology, and University of Colorado Lung SPORE. ACKNOWLEDGEMENTS ROS1 Cancer Model Project STUDY CONTACT +1 (866) 988-ROS1 [email protected] https://alcmi.net/research/ros1-pdx-study/ Scan to view the ALCMI ROS1 website *35 patient contacts to date; specimens processed within 24 hours of collection ALCMI-007 / NCT01580982 (at University of Colorado) “Molecular Analysis of Oncogenes and Resistance Mechanisms in Cancer” ALCMI-006 / NCT# pending (at Champions Oncology) “ROS1-Fusion Positive Tumors for PDX” Remote consent obtained Coordinate w/pt, ship kit to patient Return kit U. Colorado begins cell line development* Coordinate w/pt & MD, ship kit to MD Study RN collects clinical data Return kit Champions implants tumor into mouse* Remote consent obtained Biopsy Biopsy ROS1+ patient learns of upcoming biopsy Pre-screening call with study RN Patient-Derived Xenograft (PDX) models Cell line models INTRODUCTION Motivated, Engaged ROS1+ Online Community Facebook group: ROS1 Positive (ROS1+) Cancer Facebook Page: ROS1 Cancer Research Forum ROS1cancer.com • List of ROS1+ expert clinicians • Living with ROS1+ cancer • Drugs with ROS1 activity • Clinical trials for ROS1 patients Twitter: @ros1cancer, #ROS1 [email protected] GLOBAL ROS1 INITIATIVE CONTACT THE PATIENT VOICE “The ROS1 Cancer Model Project, part of the larger Global ROS1 Initiative, has the potential to powerfully impact cancer research. Patients organizing and collaborating with researchers in this manner is the future.” “The Global Initiative is a way we can contribute to research in hopes of helping others with this rare cancer.” ROS1der Patient and Caregiver Community Partnership : Patients, Clinicians, Non-Profits, Researchers, Industry 5 enrolled 8 referrals ROS1der membership as of Jan 2020 Mutations in NSCLC ROS1 3% McCoach CE, Le AT, Gowan K, et al. Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer. Clin Cancer Res. 2018;24(14):3334–3347. doi:10.1158/1078-0432.CCR-17-2452
Transcript of The ROS1 Cancer Model Project: a unique patient-driven ... · implants tumor into mouse* Remote...
METHODS
The ROS1 Cancer Model Project is part of the Global ROS1 Initiative, a powerful partnership between patients & caregivers, advocacy organizations, researchers and industry that, when combined with social media outreach, has increased the available oncogene-driven patient data, specimens, and cancer models for rare, geographically-distributed pan-cancer patient populations. Current efforts are focused on growing the number of models available and disseminating them for research.
CONCLUSIONS
The ROS1 Cancer Model Project: a unique patient-driven partnership to accelerate researchAmy C. Moore1, Lisa Goldman2, Tori Tomalia2, Robert C. Doebele3 , Christine M. Lovly4, Rachel Chiaverelli5, Tony Addario6, Alicia Sable-Hunt6, Bonne J. Addario1, Janet Freeman-Daily2
1GO2 Foundation for Lung Cancer, San Carlos, CA, 2The ROS1ders Inc., Mountain View, CA, 3University of Colorado Denver, Aurora, CO, 4Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, 5Champions Oncology Inc., Hackensack, NJ, 6Addario Lung Cancer Medical Institute, San Carlos, CA
• >500 English-speaking ROS1+ patients & caregivers
• 6 continents• 28 countries• 8 ROS1+ cancer types
Co-Creation of Preclinical
Cancer Models
Dissemination of Annotated ROS1+
Models
Collect Patient Medical Records &
Specimens
Model Creation, Analysis,
Data Interpretation
Other Tumors Can Harbor ROS1+• angiosarcoma• breast cancer• cervical cancer• cholangiocarcinoma• colon cancer• epithelioid hemangioendothelioma• gastric cancer• glioblastoma• inflammatory myofibroblastic tumor• liver cancer• melanoma• ovarian cancer• pancreatic cancer
• Rare (only 3% of NSCLC and other cancers)• Few cancer clinics or doctors are familiar with ROS1 cancer or encounter ROS1+ patients• NSCLC patients are not always tested for ROS1 (even though ROS1+ NSCLC has two FDA-
approved drugs), and other cancers are almost never tested for ROS1• ROS1 can fuse with 20+ genes, but had only 1 PDX model & a few cell lines in 01/2017
Pan-Cancer Challenges of ROS1 Rearrangements
To date we have created 8 new cell lines (which doubled the available ROS1 cell lines) and initiated 5 PDX mouse models. Three cell lines have been genomically characterized (two ROS1-CD74, one ROS1-TPM3). The cell lines have been shared with five other institutions researching ROS1 cancers: UCSF, Huntsman Cancer Institute, NIH, Moffitt Cancer Center, and Ignyta (now Roche). The cells lines have been used in three published ROS1 journal articles, among them an analysis of ROS1 resistance mechanisms to targeted therapies (left).
PRELIMINARY RESULTS
Thanks to all ROS1 clinicians, researchers, patients, caregivers, supporters, and partners who make the ROS1 Cancer Model Project possible. Jeff Wynne collected data for the ROS1der demographics. Funding and in-kind support for the Global ROS1 Initiative is provided by individual ROS1ders, Addario Lung Cancer Medical Institute, GO2 Foundation for Lung Cancer, Champions Oncology, and University of Colorado Lung SPORE.
ACKNOWLEDGEMENTS
ROS1 Cancer Model Project
STUDY CONTACT
+1 (866) [email protected]
https://alcmi.net/research/ros1-pdx-study/
Scan to view the ALCMI ROS1
website
*35 patient contacts to date; specimens processed within 24 hours of collection
ALCMI-007 / NCT01580982 (at University of Colorado)“Molecular Analysis of Oncogenes and Resistance Mechanisms in Cancer”
ALCMI-006 / NCT# pending (at Champions Oncology)“ROS1-Fusion Positive Tumors for PDX”
Remote consent obtained
Coordinate w/pt, ship kit to patient
Return kit
U. Colorado begins cell line development*
Coordinate w/pt & MD, ship kit to MD
Study RN collects clinical data
Return kit
Champions implants tumor
into mouse*Remote consent obtained
Biopsy
Biopsy
ROS1+ patient
learns of upcoming
biopsy
Pre-screening call with study RN
Patient-DerivedXenograft (PDX)
models
Cell line models
INTRODUCTIONMotivated, Engaged ROS1+ Online Community
Facebook group: ROS1 Positive (ROS1+) Cancer
Facebook Page: ROS1 Cancer Research ForumROS1cancer.com
• List of ROS1+ expert clinicians• Living with ROS1+ cancer• Drugs with ROS1 activity• Clinical trials for ROS1 patients
Twitter: @ros1cancer, #ROS1
[email protected] ROS1 INITIATIVE CONTACT
THE PATIENT VOICE
“The ROS1 Cancer Model Project, part of the larger Global ROS1 Initiative, has the potential to powerfully impact cancer research. Patients organizing and collaborating with researchers in this manner is the future.”
“The Global Initiative is a way we can contribute to research in hopes of helping others with this rare cancer.”
ROS1der Patient and Caregiver
Community
Partnership: Patients, Clinicians, Non-Profits, Researchers, Industry
5 enrolled
8 referrals
ROS1der membership as of Jan 2020
Mutations in NSCLC
ROS1 3%
McCoach CE, Le AT, Gowan K, et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018;24(14):3334–3347. doi:10.1158/1078-0432.CCR-17-2452
